Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial
(2023)
Journal Article
Abhishek, A., Peckham, N., Pade, C., Gibbons, J. M., Cureton, L., Francis, A., Barber, V., Williams, J. A. E., Appelbe, D., Eldridge, L., Julier, P., Altmann, D. M., Bluett, J., Brooks, T., Coates, L. C., Rombach, I., Semper, A., Otter, A., Valdes, A. M., Nguyen-Van-Tam, J. S., …Study investigators, V. (2024). Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial. The Lancet Rheumatology, 6(2), E92-E104. https://doi.org/10.1016/S2665-9913%2823%2900298-9
Background
Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improv...
Read More about Two-week break in methotrexate treatment and COVID-19 vaccine response: a prospective, open label, two-arm parallel-group, multicentre, superiority, randomised controlled trial.